marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
EyePoint Pharmaceuticals Balance Sheet 2011-2024 | EYPT
Annual Balance Sheet EyePoint Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-276 M | -65.8 M | -141 M | 1.4 M | 28.4 M | -21.5 M | -16.9 M | -15.3 M | -19.1 M | -15.3 M | -6.9 M | -4.62 M | -12.9 M |
Long Term Debt |
4.91 M | 29.3 M | 36.6 M | 38 M | 47.2 M | 17.3 M | - | - | - | - | - | - | - |
Long Term Debt Current |
563 K | 543 K | 645 K | 568 K | 481 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 58.3 M | 53.1 M | 38.3 M | 51 K | 5.64 M | 5.65 M | 5.62 M | 5.25 M | 3.78 M | 4.65 M |
Total Current Liabilities |
63.3 M | 34.5 M | 23.7 M | 14.9 M | 11.5 M | 21.5 M | 5.29 M | 5.09 M | 3.35 M | 2.13 M | 3.3 M | 3.18 M | - |
Total Liabilities |
88.9 M | 84 M | 79 M | 73.2 M | 64.6 M | 60 M | 5.34 M | 10.7 M | 9 M | 7.75 M | 8.55 M | 6.96 M | 9.68 M |
Deferred Revenue |
38.6 M | 1.2 M | 1.07 M | 945 K | 15 K | - | 50 K | 147 K | 33 K | 138 K | 738 K | 2.18 M | 3.21 M |
Retained Earnings |
-742 M | -671 M | -569 M | -511 M | -465 M | -364 M | -311 M | -292 M | -271 M | -277 M | -264 M | -252 M | -227 M |
Total Assets |
355 M | 180 M | 263 M | 91.7 M | 73 M | 71.7 M | 18.7 M | 31.6 M | 32.4 M | 22.7 M | 16.2 M | 20.6 M | 47.1 M |
Cash and Cash Equivalents |
281 M | 95.6 M | 179 M | 44.9 M | 22.2 M | 45.3 M | 16.9 M | 15.3 M | 19.1 M | 15.3 M | 6.9 M | 4.62 M | 12.9 M |
Book Value |
266 M | 96.4 M | 184 M | 18.5 M | 8.33 M | 11.7 M | 13.3 M | 20.9 M | 23.4 M | 14.9 M | 7.7 M | 13.6 M | 37.4 M |
Total Shareholders Equity |
266 M | 96.4 M | 184 M | 18.5 M | 8.33 M | 37.6 M | 13.3 M | 20.9 M | 23.4 M | 14.9 M | 7.7 M | 13.6 M | 37.4 M |
All numbers in USD currency
Quarterly Balance Sheet EyePoint Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
21.9 M | 22.2 M | 4.91 M | - | - | 29.4 M | 29.3 M | 29.3 M | - | 29.1 M | 36.6 M | 36.4 M | 36.2 M | 38.1 M | 38 M | 38 M | 38 M | 38 M | 47.2 M | 47.2 M | 47.2 M | 47.2 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
82.2 M | 95.9 M | 88.9 M | 101 M | 118 M | 76.2 M | 84 M | 84.1 M | - | 77.7 M | 79 M | 75.5 M | 72 M | 71.4 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 64.6 M | 64.6 M | 64.6 M | 64.6 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 4.29 M | 4.33 M | 5.34 M | 5.34 M | 4.98 M | 10.5 M | 10.7 M | 10.7 M | 9.53 M | 8.64 M | 9 M | 9 M | 7.9 M | 7.94 M | 7.75 M | 7.75 M | 8.22 M | 8.5 M | 8.55 M | 8.55 M | 7.23 M | 7.18 M | 6.96 M | 6.96 M | 7.16 M | 7.91 M | 9.68 M | 9.68 M |
Deferred Revenue |
26 M | 33.3 M | 38.6 M | 39.8 M | 42.1 M | 1.24 M | 1.2 M | 1.17 M | - | 1.1 M | 1.07 M | 1.04 M | 1.01 M | 973 K | 945 K | 945 K | 945 K | 945 K | 15 K | 15 K | 15 K | 15 K | 30 K | 30 K | 30 K | 30 K | 505 K | 10 K | 50 K | 50 K | 136 K | 139 K | 147 K | 147 K | 28 K | 33 K | 33 K | 33 K | 69 K | 104 K | 138 K | 138 K | 771 K | 688 K | 738 K | 738 K | 784 K | 2.4 M | 2.18 M | 2.18 M | 1.72 M | 2.51 M | 3.21 M | 3.21 M |
Retained Earnings |
-832 M | -802 M | -742 M | -728 M | -715 M | -693 M | -671 M | -628 M | - | -590 M | -569 M | -550 M | -533 M | -523 M | -511 M | -511 M | -511 M | -511 M | -465 M | -465 M | -465 M | -465 M | -408 M | -408 M | -408 M | -408 M | -323 M | -317 M | -311 M | -311 M | -299 M | -299 M | -292 M | -292 M | -281 M | -276 M | -271 M | -271 M | -261 M | -256 M | -277 M | -277 M | -271 M | -267 M | -264 M | -264 M | -257 M | -254 M | -252 M | -252 M | -247 M | -229 M | -227 M | -227 M |
Total Assets |
301 M | 324 M | 355 M | 160 M | 176 M | 155 M | 180 M | 220 M | - | 245 M | 263 M | 168 M | 179 M | 187 M | 91.7 M | 91.7 M | 91.7 M | 91.7 M | 73 M | 73 M | 73 M | 73 M | 78.2 M | 78.2 M | 78.2 M | 78.2 M | 14.2 M | 13.3 M | 18.7 M | 18.7 M | 19.7 M | 24.9 M | 31.6 M | 31.6 M | 24 M | 27.5 M | 32.4 M | 32.4 M | 40.2 M | 43.7 M | 22.7 M | 22.7 M | 20.8 M | 22.7 M | 16.2 M | 16.2 M | 21 M | 23.3 M | 20.6 M | 20.6 M | 24.9 M | 43.1 M | 47.1 M | 47.1 M |
Cash and Cash Equivalents |
79.8 M | 90.8 M | 281 M | 133 M | 140 M | 106 M | 95.6 M | 75.4 M | 82.1 M | 102 M | 179 M | 120 M | 128 M | 139 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 12.9 M | 11.8 M | 16.9 M | 16.9 M | 11.7 M | 14.3 M | 11.7 M | 14.3 M | 11.2 M | 14.1 M | 11.2 M | 14.1 M | 29.8 M | 11.4 M | 29.8 M | 11.4 M | 15.2 M | 14.5 M | 15.2 M | 14.5 M | 9.41 M | 8.39 M | 9.41 M | 8.39 M | 8.41 M | 9.81 M | 8.41 M | 9.81 M |
Book Value |
219 M | 228 M | 266 M | 58.6 M | 57.3 M | 78.4 M | 96.4 M | 136 M | - | 167 M | 184 M | 92.7 M | 107 M | 116 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 8.33 M | 8.33 M | 8.33 M | 8.33 M | 37.6 M | 37.6 M | 37.6 M | 37.6 M | 9.9 M | 9 M | 13.3 M | 13.3 M | 14.8 M | 14.4 M | 20.9 M | 20.9 M | 14.4 M | 18.8 M | 23.4 M | 23.4 M | 32.3 M | 35.8 M | 14.9 M | 14.9 M | 12.6 M | 14.2 M | 7.7 M | 7.7 M | 13.8 M | 16.2 M | 13.6 M | 13.6 M | 17.8 M | 35.2 M | 37.4 M | 37.4 M |
Total Shareholders Equity |
219 M | 228 M | 266 M | 58.6 M | 57.3 M | 78.4 M | 96.4 M | 136 M | 151 M | 167 M | 184 M | 92.7 M | 107 M | 116 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 8.33 M | 8.33 M | 8.33 M | 8.33 M | 37.6 M | 37.6 M | 37.6 M | 37.6 M | 9.9 M | 9 M | 9.9 M | 9 M | 14.8 M | 14.3 M | 14.8 M | 14.4 M | 14.4 M | 18.8 M | 14.4 M | 18.8 M | 32.3 M | 35.8 M | 32.3 M | 14.9 M | 12.6 M | 14.2 M | 7.7 M | 7.7 M | 13.8 M | 16.2 M | 13.6 M | 13.6 M | 17.8 M | 35.2 M | 37.4 M | 37.4 M |
All numbers in USD currency